Abstract
Pulmonary hypertension has traditionally been categorized into primary and secondary types. Although primary pulmonary hypertension (PPH) is felt to be relatively unique as a cardiopulmonary disease, its distinction from secondary forms of pulmonary hypertension often solely depends on whether or not an identifiable etiology can be ascertained. Histologically it can be impossible to distinguish primary from secondary forms of pulmonary hypertension (Pietra et al, 1989), suggesting that the distinction may be in the mechanism(s) that produce the pulmonary vascular disease with pulmonary hypertension as a common end point.
Keywords
- Pulmonary Hypertension
- Congenital Heart Disease
- Pulmonary Blood Flow
- Primary Pulmonary Hypertension
- Secondary Form
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Belardinelli, I., Under, J. and Berne, R.M., 1989, The cardiac effects of adenosine. Prog. Cardiovas. Dis. 32: 73.
Celemajer, D.S., Cullen, S. and Deanfield, J.E., 1993, Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 87: 440.
Christman, B.W., McPherson, C.D., Newman, J.H., King, J.A., Bernard, G.R., Groves, B.M., and Loyd, J.E., 1992, An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327: 70.
Cohen, M.D., Edwards, W.D., and Fuster, V., 1986, Regression in thromboembolic type of primary pulmonary hypertension during 2–1/2 years of antithrombotic therapy. J. Am. Coll. Cardiol. 7: 172.
Cremona, G., Higenbottam, T.W., and Scott, J.P., 1991, Continuous intravenous infusion of prostacyclin (PGI2) improves survival in primary pulmonary hypertension [abstract]. Am. Rev. Respir. Dis. 143: A180.
Eisenburg, P.R., Lucore, C., Kaufinann, L., Sobel, B.E., Jafife, A.S. and Rich, S., 1990, Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 82: 841.
Fuster, V., Steele, P.M., Edwards, W.D., Gersh, B.J., McGooon, M.D. and Frye, R.L., 1984, Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70: 580.
Gomez-Sanchez, M.A., Mestre, de Juan, M., Gomez-Pajuelo, C. et al, 1989, Pulmonary hypertension due to toxic oil syndrome. Chest. 95: 325.
Gurtner, H.P., 1985, Aminorex and pulmonary hypertension. Cor. Vasa. 27: 160.
Hoflman, J.I.E., Rudolf, A.M. and Heymann, M.A., 1981, Pulmonar vascular disease with congenital heart lesions: Pathologic features and causes. Circulation 64: 873.
Houston, D.S. and Vanhoutte, P.M., 1988, Comparison of serotonergic receptor subtypes on the smooth muscle and endothelin of the canine coronary artery. J. Pharmacol Exp. Ther. 244: 1.
Loyd, J.E., Atkinson, J.B., Pietra, G.G., Virmani, R. and Newman, J.H., 1988, Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. Am. Rev. Respir. Dis. 138: 952.
Loyd, J.E., Primm, R.K. and Newmann, J.H., 1984, Familial primary pulmonary hypertension: clinical patterns. Am. Rev. Respir. Dis. 129: 194.
Luscher, T.F., 1992, Endothelin: Systemic arterial and pulmonary effects of a new peptide with potent biologic properties. Am. Rev. Respir. Dis. 146: 556.
McDonnell, P. J., Toye, P. A. and Hutchins, G.M., 1983, Primary pulmonary hypertension and cirrhosis: Are they related? Am. Rev. REspir. Dis. 127: 437.
Meyrick, B. and Reid, L., 1979, Development of pulmonary arterial changes in rats fed Crotalaria Spectabilis. Am. J. Pathol 94: 37.
Miller, V.M., Aahus, L.L. and Vanhoutte, P.M., 1986, Modulation of endothelium-dependent responses by chronic alterations of blood flow. Am. J. Physiol 251: H520.
Nootens, M., Kaufinann, E. and Rich, S., 1993, Short-term effectiveness of nifedipine in secondary pulmonary hypertension. Am. J. Cardiol 72: 1475.
Palevsky, H.I., Schloo, B.L., Pietra, G.G., Weber, K.T., Janicki, J.S., Rubin, E., et al, 1989, Primary pulmonary hypertension: vascular structure, morphometry and responsiveness to vasodilator agents. Circulation 80: 1207.
Pepke-Zaba, J., Higgenbottam, W., Tuan Ding-Xuan, A., Strong, D. and Wallwork, J., 1991, Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 338: 447.
Pietra, G.G., Edwards, W.D. and Kay, J.M., et al, 1989, Histopathology of pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80: 1198.
Pietra, G.G., and Ruttner, J.R., 1987, Specificity of pulmonary vascular lesions in primary pulmonary hypertension. Respiration 52: 81.
Polos, P.G., Wolfe, D., Harley, R.A., Strange, C. and Sahn, S.A., 1992, Pulmonary hypertension and immunodeficiency virus infection. Chest 101: 474.
Rabinovitch, M., Andrew, M. and Thom, H., et al, 1987, Abnormal endothelial factor VIII associated pulmonary hypertension and congenital heart defects. Circulation 76: 1043.
Rabinovitch, M., Bothwell, T. and Hayakawa, B.N., et al, 1986, Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. Lab. Invest. 55: 632.
Reeves, J.T., Groves, B.M. and Turkevich, D., 1986, The case for treatment of selected patients with primary pulmonary hypertension. Am. Rev. Respir. Dis. 134: 342.
Rich, S., Kaufinann, E. and Levy, P.S., 1992, The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl J. Med. 327: 76.
Roberts, J.D., Lang, P., Bigatello, L.M., Vlahakes, G.J. and Zapol, W.M., 1993, Inhaled nitric oxide in congenital heart disease. Circulation 87: 447.
Rubin, L.J., Mendoza, J., Hood, M., McGoon, M., Barst, R. and Williams, W.B., et al, 1990, Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann. Intern. Med. 112: 485.
Ryan, U.S., 1986, The endothelial surface and responses to injury. Fed. Proc. 45: 101.
Samet, P. and Bernstein, W.H., 1963, Loss of reactivity of the pulmonary vascular bed in primary pulmonary hypertension. Am. Heart J. 66: 197.
Schrader, B.J., Inbar, S., Kaufinann, L., Vestal, R.E. and Rich, S., 1992, Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J. Am. Coll Cardiol 19: 1060.
Stelzner, T.J., O’Brien, R.F., Yanagisawa, M., Sakurai, T., Sato, K., Webb, S., Zamora, M., McMurtry, I.F. and Fisher, J.H., 1992, Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am. J. Physiol L614.
Stewart, D.J., Levy, R.D., Cernacek, P. and Langleben, D., 1991, Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease. Ann. Intern. Med. 114: 464.
Tracy, P.B., 1991, The role of endothelium in the expression of procoagulant activity. Coronary Artery Disease 2: 146.
Ungerer, R.G., Tashkin, D.P., Furst, D., et al, 1983, Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am. J. Med. 75: 65.
Wood, P., 1958 Pulmonary hypertension with special reference to the vasoconstrictive factor. Br. Heart J. 20: 557.
Yamaki, S., Horiuchi, T., Miura, M., et al, 1986, Pulmonary vascular disease in secundum atrial septal defect with pulmonary hypertension. Chest. 89: 694.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Plenum Press, New York
About this chapter
Cite this chapter
Rich, S. (1996). The Cellular Basis of the Pathophysiology and Treatment of Pulmonary Hypertension. In: Catravas, J.D., Callow, A.D., Ryan, U.S. (eds) Vascular Endothelium. NATO ASI Series, vol 281. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0355-8_13
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0355-8_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8013-9
Online ISBN: 978-1-4613-0355-8
eBook Packages: Springer Book Archive